Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Once Daily YM150, an Oral Direct Factor Xa Inhibitor, for Prevention of Venous Thromboembolism in Patients Undergoing Elective Primary Hip Replacement.

Bengt I. Eriksson, MD, PhD, Alexander G.G. Turpie, MD, PhD, Michael R. Lassen, MD, PhD, Martin H. Prins, MD, PhD, Giancarlo Agnelli, MD, PhD, Peter Kälebo, MD, PhD, Graham Wetherill, MSc, Lambertus Meems, MSc.

Blood (2007) 110 (11): 309.

https://doi.org/10.1182/blood.V110.11.309.309

Published: 2007

Journal Articles

Rivaroxaban for Thromboprophylaxis in Patients Undergoing Total Hip Replacement: Comparison of Pharmacokinetics and Pharmacodynamics with Once- and Twice-Daily Dosing.

Wolfgang Mueck, PhD, Bengt I. Eriksson, MD, PhD, Lars C. Borris, MD, Ola E. Dahl, MD, PhD, Sylvia Haas, MD, Menno V. Huisman, MD, PhD, Ajay K. Kakkar, MD, PhD, Peter Kälebo, MD, PhD, Eva Muehlhofer, PhD, Frank Misselwitz, MD, PhD

Blood (2006) 108 (11): 903.

https://doi.org/10.1182/blood.V108.11.903.903

Published: 2006

Journal Articles

VENUS - A Study To Validate Centrally Adjudicated Venous Ultrasound Against Venography after Major Orthopaedic Surgery.

Sebastian M. Schellong, MD, Jan Beyer, MD, Kai Halbritter, MD, Benjamin Schmidt, MD, Alexander G.G. Turpie, MD, Bengt I. Eriksson, MD, PhD, Frank Misselwitz, MD, PhD, Peter Kälebo, MD

Blood (2005) 106 (11): 281.

https://doi.org/10.1182/blood.V106.11.281.281

Published: 2005

Journal Articles

Thromboprophylaxis after Orthopaedic Surgery with an Oral, Direct Factor Xa Inhibitor: Pooled Results of Two Phase Iib Clinical Trials.

Alexander G.G. Turpie, MD, Kenneth Alan Bauer, MD, Lars Borris, MD, Ola E. Dahl, MD, PhD, William D. Fisher, MD, Michael Gent, MD, PhD, Sylvia Haas, MD, Menno V. Huisman, MD, PhD, Ajay K. Kakkar, MD, PhD, Peter Kälebo, MD, PhD, Louis M. Kwong, MD, Martin Homering, PhD, Frank Misselwitz, MD, PhD, Bengt I. Eriksson, MD, PhD

Blood (2005) 106 (11): 277.

https://doi.org/10.1182/blood.V106.11.277.277

Published: 2005

Journal Articles

Prevention of Venous Thromboembolism after Total Hip Replacement with Once-Daily BAY 59-7939 - An Oral, Direct Factor Xa Inhibitor.

Bengt I. Eriksson, MD, PhD, Lars Borris, MD, Ola E. Dahl, MD, PhD, Sylvia Haas, MD, Menno V. Huisman, MD, PhD, Ajay K. Kakkar, MD, PhD, Frank Misselwitz, MD, PhD, Eva Muehlhofer, PhD, Peter Kälebo, MD, PhD

Blood (2005) 106 (11): 280.

https://doi.org/10.1182/blood.V106.11.280.280

Published: 2005

NARROW

Once Daily YM150, an Oral Direct Factor Xa Inhibitor, for Prevention of Venous Thromboembolism in Patients Undergoing Elective Primary Hip Replacement.

Rivaroxaban for Thromboprophylaxis in Patients Undergoing Total Hip Replacement: Comparison of Pharmacokinetics and Pharmacodynamics with Once- and Twice-Daily Dosing.

VENUS - A Study To Validate Centrally Adjudicated Venous Ultrasound Against Venography after Major Orthopaedic Surgery.

Thromboprophylaxis after Orthopaedic Surgery with an Oral, Direct Factor Xa Inhibitor: Pooled Results of Two Phase Iib Clinical Trials.

Prevention of Venous Thromboembolism after Total Hip Replacement with Once-Daily BAY 59-7939 - An Oral, Direct Factor Xa Inhibitor.

Email alerts

ASH Publications

American Society of Hematology

Once Daily YM150, an Oral Direct Factor Xa Inhibitor, for Prevention of Venous Thromboembolism in Patients Undergoing Elective Primary Hip Replacement.

Rivaroxaban for Thromboprophylaxis in Patients Undergoing Total Hip Replacement: Comparison of Pharmacokinetics and Pharmacodynamics with Once- and Twice-Daily Dosing.

VENUS - A Study To Validate Centrally Adjudicated Venous Ultrasound Against Venography after Major Orthopaedic Surgery.

Thromboprophylaxis after Orthopaedic Surgery with an Oral, Direct Factor Xa Inhibitor: Pooled Results of Two Phase Iib Clinical Trials.

Prevention of Venous Thromboembolism after Total Hip Replacement with Once-Daily BAY 59-7939 - An Oral, Direct Factor Xa Inhibitor.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only